539 related articles for article (PubMed ID: 29220291)
21. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas.
Dancsok AR; Setsu N; Gao D; Blay JY; Thomas D; Maki RG; Nielsen TO; Demicco EG
Mod Pathol; 2019 Dec; 32(12):1772-1785. PubMed ID: 31263176
[TBL] [Abstract][Full Text] [Related]
22. Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention.
Tazzari M; Bergamaschi L; De Vita A; Collini P; Barisella M; Bertolotti A; Ibrahim T; Pasquali S; Castelli C; Vallacchi V
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299136
[TBL] [Abstract][Full Text] [Related]
23. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
24. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
25. Microbial biomarkers for immune checkpoint blockade therapy against cancer.
Adachi K; Tamada K
J Gastroenterol; 2018 Sep; 53(9):999-1005. PubMed ID: 30003334
[TBL] [Abstract][Full Text] [Related]
26. Future directions in soft tissue sarcoma treatment.
Hall F; Villalobos V; Wilky B
Curr Probl Cancer; 2019 Aug; 43(4):300-307. PubMed ID: 31229264
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapeutic approaches to sarcoma.
Linehan DC; Bowne WB; Lewis JJ
Semin Surg Oncol; 1999; 17(1):72-7. PubMed ID: 10402640
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
29. Soft tissue sarcoma as a model disease to examine cancer immunotherapy.
Maki RG
Curr Opin Oncol; 2001 Jul; 13(4):270-4. PubMed ID: 11429485
[TBL] [Abstract][Full Text] [Related]
30. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
Brahmi M; Vanacker H; Dufresne A
Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
[TBL] [Abstract][Full Text] [Related]
32. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
33. Clinical and immunological characteristics of sarcomas patients with clonogenic tumors.
Avdonkina NA; Danilova AB; Nekhaeva TL; Prosekina EA; Emelyanova NV; Novik AV; Girdyuk DV; Gafton GI; Baldueva IA
Immunobiology; 2021 Jul; 226(4):152094. PubMed ID: 34052775
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
35. Immunity against soft-tissue sarcomas.
Maki RG
Curr Oncol Rep; 2003 Jul; 5(4):282-7. PubMed ID: 12781069
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in soft-tissue sarcoma.
Ayodele O; Razak ARA
Curr Oncol; 2020 Feb; 27(Suppl 1):17-23. PubMed ID: 32174754
[TBL] [Abstract][Full Text] [Related]
37. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2023 May; 23(5):495-502. PubMed ID: 37017995
[TBL] [Abstract][Full Text] [Related]
38. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
40. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
Sebio A; Wilky BA; Keedy VL; Jones RL
Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]